Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.
about
Ketamine and other glutamate receptor modulators for depression in adultsOxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant ApproachesNegative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic WindowCell atrophy and loss in depression: reversal by antidepressant treatmentGABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.Glutamate and its receptors in the pathophysiology and treatment of major depressive disorderTest-retest reproducibility of the metabotropic glutamate receptor 5 ligand [¹⁸F]FPEB with bolus plus constant infusion in humansGene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects.Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [(11)C]ABP688 and magnetic resonance spectroscopyDecreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder.Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics.New targets for rapid antidepressant action.Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression.In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [(11) C]ABP688 PET imagingIn vivo imaging of mGluR5 changes during epileptogenesis using [11C]ABP688 PET in pilocarpine-induced epilepsy rat modelThe mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorderThe role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies.An excitatory synapse hypothesis of depressionComparative assessment of parametric neuroreceptor mapping approaches based on the simplified reference tissue model using [¹¹C]ABP688 PET.Major depressive disorder and alterations in insular cortical activity: a review of current functional magnetic imaging research.Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress.Novel Glutamatergic Treatments for Severe Mood Disorders.Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomographyGABAergic control of depression-related brain statesReduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway.Studies of the metabotropic glutamate receptor 5 radioligand [¹¹C]ABP688 with N-acetylcysteine challenge in rhesus monkeys.The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related DisordersMetabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans.Surface-based regional homogeneity in first-episode, drug-naïve major depression: a resting-state FMRI studyHigh-field magnetic resonance imaging of structural alterations in first-episode, drug-naive patients with major depressive disorder.Investigational NMDA receptor modulators for depression.Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention.Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors.Positron emission tomography molecular imaging in late-life depression.Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis.
P2860
Q24186746-583E2F50-477E-4E1A-8E8C-21DC6341BFD7Q26738789-5323BB8B-6EEA-4F6E-B321-D636B04A111DQ26775243-9A42844E-4D68-43F3-A55A-9ACA7F6C63B3Q27013609-C358A84B-9568-43E8-A17B-032C2E363405Q30363617-FBD2D329-C157-4098-A340-A6C22B7CD847Q30685335-B75DB814-8DB8-41F6-8466-F113D1AFC433Q30711088-0B42F258-DF77-4538-ADA1-C0BDE7D1EC7FQ33786437-B46FD183-2B78-4A53-A479-28836A0E3A8FQ33874356-3C1E2646-B3FC-4833-B92B-130D3F340895Q33930038-B44C96B8-0851-418F-8F06-4EDF47E14ED5Q34181837-336357A1-640C-47FD-9927-F18733BDA169Q34429155-7EC62879-8EDC-4629-8F45-89A4D2DFE4FCQ34507177-55C9C805-2020-4D3D-A74D-234137B9D40DQ34778847-DAE8DB72-AC83-4311-B05B-6CF53C7151CEQ34778858-A616F14B-B898-4BB0-8C4A-34F665D3CE9FQ35058637-C6537B79-3773-4EC3-B8D3-570B5FB868E1Q35129804-D97C1EA4-CCA6-49DC-8DBE-94E83CED2138Q35159668-2F5398B0-474D-4E6F-B9CB-AC0858CBD581Q35190052-FB01F2B9-5065-46D3-AABA-305CBF38D72BQ35563515-98E1FE81-65F4-48E3-B71A-E9F37CFF8387Q36350532-ADD5F388-BFCD-4A77-9CC5-CC9CA1DF381DQ36439675-112154CF-75F8-47E3-84C0-6FB1DC3E21D3Q36460302-49C1C7D6-CEA2-45A4-8B87-CEEF783DEFBFQ36498659-2F734D6E-B91C-400F-8663-7E3C392F0058Q36535202-8469F35A-5C64-4790-9BA0-129CFB961C34Q36668325-0F036457-D5D8-4A9C-A7A1-6C8D7ED74079Q36808854-F9FEDA14-C542-4261-8ACF-12540E3617FCQ36956648-4DAEF480-920E-42E6-80D7-42B5ABC54AA8Q37008461-7D625C6A-3DC0-4E0C-B639-03C4D4B6926CQ37172873-F9349C14-0FCC-4D77-9320-33C953EC4293Q37344213-C7EB182B-2473-4078-A7B9-21D448C8CB32Q37347468-5F0967C9-7B44-4DB5-BCE6-33678B4E5D07Q37591594-9565BF51-455A-42FC-BDF9-C3270F44733FQ37639865-17D03B4E-A811-413E-B96E-3EB7BFEA3C53Q37648259-9BF406BF-4C99-47F2-844E-1638DD2A2B27Q37957965-D96688B4-63F2-4616-88DF-0E00C5011712Q37973223-CA0169A3-9371-42C6-A6FE-75A014665292Q38166973-EE6D34E7-966C-4C11-A3AF-00BE3110B0D2Q38176164-FD96A5A8-FC1C-4568-A6FF-6F636CD22509Q38194251-3A5E49E6-9ABF-4A0D-A314-45C9D13D2432
P2860
Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@ast
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@en
type
label
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@ast
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@en
prefLabel
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@ast
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@en
P2093
P2860
P50
P1476
Reduced metabotropic glutamate ...... P688 PET and postmortem study.
@en
P2093
Alexandra Deschwanden
Alfred Buck
Anass Johayem
Beata Karolewicz
Craig A Stockmeier
Cyrill Burger
Judit Sovago
Simon M Ametamey
P2860
P304
P356
10.1176/APPI.AJP.2011.09111607
P407
P577
2011-04-15T00:00:00Z